Combination Therapy Using Chelating Agent and Zinc for Wilson's Disease
Jui-Chi Chen1, Cheng-Hung Chuang2, Jing-Doo Wang3
1Department of Computer Science and Information Engineering, Asia University, Taichung, 41354 Taiwan.
Journal of Medical and Biological Engineering
|December 23, 2015
Summary
Combination therapies for Wilson's disease (WD) show varied effectiveness. Penicillamine plus zinc sulfate increased mortality, necessitating careful monitoring of WD patients, especially those with hepatic issues.
Area of Science:
- Hepatology
- Pharmacology
- Genetics
Background:
- Wilson's disease (WD) treatment lacks a global standard.
- Current therapies often combine chelating agents with zinc.
- Effectiveness of combination therapies requires systematic evaluation.
Conclusions:
- Combination therapies for WD require careful patient monitoring.
- Hepatic Wilson's disease manifestations respond less effectively to combination therapy.
- Higher mortality associated with penicillamine and zinc sulfate necessitates caution.
Related Concept Videos
Extraction: Advanced Methods
1.3K
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.3K
Masking and Demasking Agents
4.0K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
4.0K
Chronic Pancreatitis II: Collaborative Care
479
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
479
EDTA: Auxiliary Complexing Reagents
1.6K
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
1.6K
Anticholinesterase Agents: Poisoning and Treatment
1.9K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.9K
Antidotes
1.3K
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
1.3K


